Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-gp100 TCR Gene Therapy for Metastatic Melanoma
NCT00509496Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Jul 2011
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gp100:154-162 reactive peripheral blood lymphocytes in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Tumor Regression at 20 months. Started Jun 2007; status: terminated.
02
Drugs
gp100:154-162 reactive peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00509496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509496.